Cencora, Inc. $COR Shares Sold by Beutel Goodman & Co Ltd.

Beutel Goodman & Co Ltd. trimmed its holdings in Cencora, Inc. (NYSE:COR) by 34.8% during the second quarter, Holdings Channel.com reports. The fund owned 332,952 shares of the company’s stock after selling 177,824 shares during the period. Beutel Goodman & Co Ltd.’s holdings in Cencora were worth $99,835,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in COR. Atlantic Edge Private Wealth Management LLC raised its position in Cencora by 70.0% during the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after acquiring an additional 35 shares during the last quarter. Costello Asset Management INC purchased a new stake in Cencora during the 1st quarter worth about $28,000. Vermillion & White Wealth Management Group LLC raised its stake in Cencora by 69.4% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after purchasing an additional 43 shares during the last quarter. Twin Peaks Wealth Advisors LLC purchased a new position in Cencora in the 2nd quarter valued at about $52,000. Finally, Hantz Financial Services Inc. boosted its stake in shares of Cencora by 712.0% during the 2nd quarter. Hantz Financial Services Inc. now owns 203 shares of the company’s stock worth $61,000 after purchasing an additional 178 shares during the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Cencora

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $366.64, for a total value of $1,868,397.44. Following the sale, the chief executive officer directly owned 65,746 shares in the company, valued at approximately $24,105,113.44. This trade represents a 7.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. This trade represents a 9.30% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 46,640 shares of company stock valued at $14,099,338. 10.80% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. JPMorgan Chase & Co. boosted their price target on Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Mizuho raised their target price on shares of Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. TD Cowen upped their price target on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Wells Fargo & Company increased their price target on shares of Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Finally, Evercore ISI set a $400.00 price target on shares of Cencora and gave the company an “outperform” rating in a report on Thursday, November 6th. Eight investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and an average price target of $371.09.

Cencora Stock Performance

NYSE:COR opened at $337.43 on Friday. The firm has a 50-day moving average of $339.40 and a two-hundred day moving average of $309.16. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55. The stock has a market cap of $65.42 billion, a P/E ratio of 42.44, a PEG ratio of 1.59 and a beta of 0.63. Cencora, Inc. has a 1-year low of $223.92 and a 1-year high of $377.54.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping the consensus estimate of $3.79 by $0.05. The business had revenue of $83.73 billion for the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were issued a $0.60 dividend. This is an increase from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend was Friday, November 14th. Cencora’s dividend payout ratio is presently 30.19%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.